Highlights•The epidermal growth factor (EGFR) is a therapeutic option for patients with all
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …

The epidermal growth factor receptor (EGFR) and RAS/RAF signaling pathway plays pivotal
roles in tumor progression via proliferation, survival, invasion, and immune evasion. Two …

Despite significant progress in management of metastatic colorectal cancer (mCRC)
pertaining to better screening procedures and amelioration of the therapeutic …

Colorectal cancer (CRC) is a significant cause of cancer-related morbidity and mortality all
over the world. Improvements of cytotoxic and biologic agents have prolonged the survival in …

Simple Summary The survival of patients with metastatic colorectal cancer (mCRC) has
been improved over the years and now reaches 30–40 months. However, few therapeutic …

The prognosis of patients with metastatic colorectal cancer (mCRC) remain poor despite the
impressive improvement of treatments observed over the last 20 years that led to an …

The advent of the epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies
(mAbs), cetuximab and panitumumab has expanded the range of treatment options for …

Outcomes for metastatic colorectal cancer (mCRC) patients have been improved by
treatment with anti-epidermal growth factor receptor (anti-EGFR) antibodies, particularly …

The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth
factor receptor (EGFR) have expanded the range of treatment options for metastatic …

Background. Survival of patients with metastatic colorectal cancer (mCRC) has been
significantly improved with the introduction of the monoclonal antibodies targeting the …